Device / Technology News

RSS

MEDSEEK to enhance online experience for UNC Health Care patients

MEDSEEK, the industry's only provider of the eHealth ecoSystem, today announced its engagement to enhance the online experience for UNC Health Care patients.

30 Apr 2010

pSivida announces presentations on bioerodible technologies for degenerative eye disease

pSivida Corp., a leader in the development of back of the eye drug delivery systems, today announced that two poster presentations will be made at the upcoming ARVO meeting on one of pSivida's next generation bioerodible technologies for degenerative eye disease. It marks a key step toward the ability to use pSivida's bioerodible technologies to develop treatments for glaucoma and other degenerative eye diseases, diseases that affect millions of Americans.

30 Apr 2010

Self-sealing sleeve for wound protection

As the days get longer and temperatures rise, so do incidences of outdoor-related injuries.

30 Apr 2010

NLV Partners closes second tranche of $26 million Series D financing in Oxford Immunotec

New Leaf Venture Partners (NLV Partners) announced today the closing of the second tranche of a $26 million investment in Oxford Immunotec Ltd., a leading manufacturer and marketer of T cell-based diagnostic tests. The Series D financing was led by NLV Partners, and additional participants included new investor Kaiser Permanente Ventures and existing investors Clarus Ventures, Wellington Partners, Kuwait-based National Technology Enterprises Company, SPARK Ventures, DFJ Esprit, Oxford University and The Dow Chemical Company.

30 Apr 2010

Study confirms MammaPrint's capabilities in determining patients likely to benefit from chemotherapy

Today, at the 11th Annual Meeting of the American Society of Breast Surgeons, Agendia, a world leader in molecular cancer diagnostics, announced that Breast Cancer Research and Treatment has published an important study demonstrating the benefit of adjuvant chemotherapy for patients with a high-risk of breast cancer recurrence according to the MammaPrint test. The ASBS meeting takes places April 28 - May 2, 2010, at the Bellagio in Las Vegas, where you can meet the Agendia team at booth # 314.

30 Apr 2010

CTCA installs Calypso's real-time tumor tracking technology at Southwestern Regional Medical Center

Calypso Medical Technologies, Inc., a developer of non-ionizing real-time localization technology used for the precise tracking of tumor targets, and Cancer Treatment Centers of America, a national network of hospitals providing a comprehensive, fully integrative approach to cancer treatment, announced today that with the installation of the Calypso System at the CTCA at Southwestern Regional Medical Center in Tulsa, Okla., Calypso's real-time tumor tracking technology is now available at all CTCA centers nationwide.

30 Apr 2010

CDC presents clinical trial results of Biojector 2000 at 13th Annual Conference on Vaccine Research

Bioject Medical Technologies Inc., a leading developer of needle-free injection therapy systems (NFITS), today announced that the Centers for Disease Control and Prevention (CDC) and its collaborating institutions presented the latest results of its clinical trial of the Biojector® 2000 at the 13th Annual Conference on Vaccine Research, sponsored by the National Foundation for Infectious Diseases and held in Bethesda, Maryland April 26 - 28, 2010.

30 Apr 2010

Elekta Neuromag tool to be highlighted at AANS 2010 Annual Meeting

At the 2010 American Association of Neurological Surgeons Annual Meeting, May 1-5 at the Pennsylvania Convention Center, Elekta will host a series of presentations highlighting Elekta Neuromag, a tool that measures and records brain activity using magnetoencephalography technology.

From Elekta 30 Apr 2010

microRNAs serve as biomarkers for lung tumor classification: Study

Rosetta Genomics, Ltd., a leading developer and provider of microRNA-based molecular diagnostic tests, announces the publication of a study showing microRNA expression differentiates between primary lung tumors and metastases to the lung. The study, entitled, "MicroRNA expression differentiates between primary lung tumors and metastases to the lung," was published in the online edition of Pathology Research and Practice on April 28, 2010.

30 Apr 2010

UIC introduces new "no stress" diagnostic system for heart failure assessment

The University of Illinois Medical Center at Chicago is the first academic medical center in the country to introduce a new "no stress" diagnostic system for assessing patients with heart failure and optimizing their treatment.

30 Apr 2010

NWO awards 31 grants in Investment Subsidy NWO Medium programme

The Netherlands Organisation for Scientific Research (NWO) has awarded 31 grants in the Investment Subsidy NWO Medium programme for the acquisition of equipment, the setting up of data collections and the production of software and bibliographies. The total investment amounts to 10 million euro.

30 Apr 2010

New tool to detect inflammatory eye disease at molecular level before damage occurs

Forget what you know about how diseases are diagnosed-new research published in the May 2010 print issue of The FASEB Journal details a noninvasive ground-breaking tool that detects signs of disease at early molecular stages before symptoms can be seen using traditional methods.

30 Apr 2010

CT Dose Summit to establish freely available guidelines for performing CT scans

A national "CT Dose Summit" in Atlanta, GA this week will bring together some of the world's leading experts on medical imaging to lay the foundation for assembling optimized guidelines for performing CT scans -- a common medical imaging procedure that uses X-rays to show cross-sectional images of the body.

30 Apr 2010

States move to require ultrasounds before abortions

Various states have passed or are considering bills to tighten abortion regulations.

30 Apr 2010

Generex Biotechnology receives U.S. patent for method of administering insulin to the buccal region

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has received a new patent in the United States.

30 Apr 2010

CSI announces completion of enrollment in CALCIUM 360° clinical trial for PAD

Cardiovascular Systems, Inc. (CSI), has completed patient enrollment in its prospective, randomized CALCIUM 360° clinical trial, part of the company's 360° Clinical Series. The CALCIUM 360° feasibility study is evaluating the treatment of peripheral arterial disease (PAD) behind and below the knee using CSI's Diamondback 360® System, a minimally invasive catheter for treating PAD anywhere in the leg. Dr. Nicolas Shammas, an interventional cardiologist at Trinity Medical Center, Bettendorf, Iowa, is the study's principal investigator.

30 Apr 2010

EndoChoice granted FDA marketing clearance for BONASTENT Esophageal and Biliary Stent platforms

EndoChoice, Inc. today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its BONASTENT® Fully Covered Esophageal Stent for the treatment of malignant esophageal obstructions, and its BONASTENT Uncovered Biliary Stent for the treatment of malignant biliary obstructions.

30 Apr 2010

A crystal ball into your future health!

Imagine knowing just what diseases you are likely to suffer from in your lifetime thanks to the sequencing of your genes. That is exactly what Professor Stephen Quake knows, because he has had his entire genome sequenced and studied. In fact he was in the news last year as well when he used new technology to sequence his genetic code for less than $50,000.

29 Apr 2010

ZOLL Medical's second-quarter revenues up 15% to $107.1 million

ZOLL Medical Corporation, a manufacturer of resuscitation devices and software solutions, today announced that revenues for the second quarter of fiscal 2010 increased 15% to $107.1 million, compared to revenues in the second quarter of last year of $92.7 million. Revenue results included a positive foreign exchange impact of approximately $2.2 million, compared to the second quarter of fiscal 2009.

29 Apr 2010

IMD seeks FDA regulatory clearance for NADiA ProsVue prostate cancer prognostic test

IRIS International, Inc., a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that its IRIS Molecular Diagnostics (IMD) subsidiary has submitted a 510(k) pre-market notification application to the U.S. Food and Drug Administration (FDA) requesting regulatory clearance for NADiA®ProsVue™, a prostate cancer prognostic test. The test is designed to help physicians identify patients at low risk of cancer recurrence post radical prostatectomy.

29 Apr 2010

Device / Technology News

MEDSEEK to enhance online experience for UNC Health Care patients

pSivida announces presentations on bioerodible technologies for degenerative eye disease

Self-sealing sleeve for wound protection

NLV Partners closes second tranche of $26 million Series D financing in Oxford Immunotec

Study confirms MammaPrint's capabilities in determining patients likely to benefit from chemotherapy

CTCA installs Calypso's real-time tumor tracking technology at Southwestern Regional Medical Center

CDC presents clinical trial results of Biojector 2000 at 13th Annual Conference on Vaccine Research

Elekta Neuromag tool to be highlighted at AANS 2010 Annual Meeting

microRNAs serve as biomarkers for lung tumor classification: Study

UIC introduces new "no stress" diagnostic system for heart failure assessment

NWO awards 31 grants in Investment Subsidy NWO Medium programme

New tool to detect inflammatory eye disease at molecular level before damage occurs

CT Dose Summit to establish freely available guidelines for performing CT scans

States move to require ultrasounds before abortions

Generex Biotechnology receives U.S. patent for method of administering insulin to the buccal region

CSI announces completion of enrollment in CALCIUM 360° clinical trial for PAD

EndoChoice granted FDA marketing clearance for BONASTENT Esophageal and Biliary Stent platforms

A crystal ball into your future health!

ZOLL Medical's second-quarter revenues up 15% to $107.1 million

IMD seeks FDA regulatory clearance for NADiA ProsVue prostate cancer prognostic test

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Latest News